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The L-arginine pathway within endothelial cells in the blood vessel wall is the source of production of the endogenous
nitrovasodilator, nitric oxide (NO). NO is released under basal conditions and in response to various stimuli such as
shear stress and in response to platelet-derived products, coagulation factors and hormones. NO is the mediator of
endothelium-dependent relaxation in the circulation and exerts its effects by activating soluble guanylyl cyclase in vas-
cular smooth muscle, which in turn leads to the formation of cyclic guanosine monophosphate (cGMP) and to relax-
ation. In addition to its effects on vascular smooth muscle, NO is also released abluminally to interact with circulating
platelets. Increases in cGMP in platelets are associated with a decreased adhesion and aggregation of cells. Thus,
endothelium-derived NO, through its vasodilator and anti-aggregatory properties, prevents vasospasm and thrombus
formation in the circulation and thereby helps to maintain blood flow to vital organs such as the heart. Therapeutic
nitrates also exert their effects by releasing NO from their molecules and activating soluble guanylyl cyclase. Their
effects are particularly pronounced in arteries without endothelium and are reduced in the presence of the basal for-
mation of endothelium-derived NO in intact arteries. The lower basal formation of endothelium-derived NO in veins,
as compared to arteries, contributes to the greater sensitivity of venous circulation to nitrates.
Thus, the endothelial L-arginine pathway plays an important protective role in the local regulation of blood flow
and through its vasodilator and antiplatelet properties.
Introduction
Ever since Thomas Lauder-Brunton first introduced
amylnitrate into clinical medicine11', nitrovasodilators of
different classes have been extensively used in the med-
ical treatment of angina pectoris, myocardial infarction
and heart failure!2"41. Understanding the mechanisms of
action of nitrates has been greatly expanded in the last
decade, particularly since the discovery of endothelium-
dependent relaxation and its mediator, the endogenous
nitrovasodilator, NO15'6'. This review summarizes cur-
rent knowledge of the endothelial L-arginine/NO path-
way in the human circulation and updates previous
articles'7'.
Endothelium-dependent vasodilation
In isolated blood vessels, as well as in the intact organ-
ism, endothelium-dependent relaxation or vasodilata-
tion occurs respectively in response to physical,
chemical and hormonal stimuli (Fig. I)!6'8"12'. Indeed,
acetylcholine relaxes or dilates conduit arteries and
increases local blood flow when infused intra-arteri-
al]y|i3.i4] jn t n e circulation of the human forearm, intra-
arterial infusion of acetylcholine causes a pronounced
increase in blood flow, unaffected by acetylsalicylic acid
(which inhibits the formation of prostacyclin) or by
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phentolamine (which excludes a contribution by the
prejunctional inhibitory effects of the muscarinic ago-
nist on adrenergic neurotransmission)''4'. Similarly, in
sympathectomized animals, the vasodilator response to
intra-arterial acetylcholine is maintained1151. Thus, the
vasodilator effects of acetylcholine are not mediated by
prostacyclin and are independent of the sympathetic
nervous system, but are reduced or prevented by
removal of the endothelium or by inhibitors of the for-
mation or action of endothelium-derived NO15'.
Nature of endothelium-derived relaxing factor (EDRF)
Interaction between the endothelium and vascular
smooth muscle cells could occur either by direct cell-to-
cell contact116171 or by local mediators. In conduit arter-
ies, the release of an endothelium-derived relaxing
factor(s) (EDRF) has been demonstrated using a 'sand-
wich' preparation of the rabbit aorta18' and confirmed
with cascade-bioassay techniques using perfused blood
vessels with endothelium or endothelial cells in culture
as donor tissues'18"23'. Since endothelium-dependent
relaxation induced by acetylcholine is unaffected by
inhibitors of cyclo-oxygenase and purinergic antago-
nists, prostaglandins or adenosine'5-6-8' can be excluded
as mediators.
Experiments in which the transit time between the
donor segment with endothelium and the bioassay tis-
sue without endothelium can be varied, allowed the bio-
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Figure 1 Endothelium-dependent relaxation with serotonin in the porcine coronary artery. In isolated rings (pretreated with
the 5-HT; serotonergic antagonist, ketanserin. to inhibit the direct contractile effects of serotonin), serotonin causes a con-
centration-dependent and complete relaxation. After pretreatment of the blood vessel with L-N°-monomethyl arginine (L-
NMMA; the inhibitor of NO formation), the response to serotonin is markedly reduced. While D-argine (D-Arg) does not
restore the response. L-arginine (L-Arg; the precursor for the formation of NO) fully restores the response. (Reproduced
with permission1"*1).
logical half-life of EDRF to be estimated, which is in the
range of a few seconds151. The scavenger of superoxide
anions, superoxide dismutase, markedly stabilizes
EDRFl21:4' indicating that the oxygen-derived free radi-
cal, superoxide anion, inactivates the factor. This obser-
vation and the stimulatory effect of the factor on soluble
guanylyl cyclase (with concomitant formation of cGMP)
led to the proposal1252''1 that EDRF is the radical NO
(Fig. 2). Similar to EDRF, NO is labile with a half-life of
a few seconds, its biological activity (relaxing effect) is
blocked by haemoglobin and superoxide anions, but
enhanced by superoxide dismutase. The chemical and
biological similarities between EDRF and NO in a vari-
ety of isolated blood vessels supports the concept that
EDRF is identical to NO1271. In line with that interpreta-
tion, cultured endothelial cells exposed to bradykinin
release NO and the amount of the radical liberated (as
measured by chemiluminescence) can explain the bio-
logical activity of EDRF|:7L Release of NO in response
to acetylcholine and the Ca:* ionophore A23187 has
also been demonstrated in the intact rabbit aorta12"1.
Debate continues on whether NO is released as such or
together with a carrier molecule (for instance the amino
acid L-cysteine to yield L-nitrosocysteine12M1).
Formation of endothelium-derived NO
In porcine endothelial cells in culture, NO is formed
from the amino acid L-arginine (Fig. 2;13"-1'1). Cultured
endothelial cells deprived of L-arginine lose their ability
to release NO, while administration of L-arginine
restores this response13"1. In arteries obtained from
experimental animals and humans, endothelium-depen-
dent relaxation by acetylcholine is inhibited by the ana-
logue of the amino acid L-NG-monomethyl arginine (L-
NMMA) and restored by the addition of L-arginine
(Figs 1 and 3:i<2"'). L-NMMA. but not its enantiomer
D-NMM A, induced endothelium-dependent contractions
in intramyocardial coronary arteries (Fig. 4;'33') and
markedly increases arterial blood pressure in rabbits'341;
in addition, the analogue of L-arginine inhibits the
hypotensive effect of acetylcholine1'41. Blood vessels
obtained from animals treated with L-NMMA have a
Figure 2 The endothelial L-arginine/NO pathway. The endoge-
nous nitrovasodilator. NO. is formed from L-arginine within
endothelial cells and released both luminally and abluminally. In
vascular smooth muscle cells. NO activates soluble guanylyl cyclase
(sGC) and in turn leads to the formation of cyclic GMP. the second
messenger mediating relaxation. In platelets, increased levels of
cyclic GMP are associated with a decreased adhesion and aggrega-
tion of the cells. Therapeutic nitrates such as organic nitrates
(R-O-NO;) or sydnonimines (SIN-1: the active metabolite of mol-
sidomine) directly activate sGC by releasing NO from their
molecules. In contrast to SIN-1. organic nitrates have to undergo a
biotransformation requiring thiol groups. (Reproduced with per-
mission1^1).
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Figure 3 Endothelium-dependent relaxation of acetylcholine in the human
internal mammary artery. Under control conditions, acetylcholine causes full
relaxation, but is inhibited by the formation of prostaglandins indomethacin. The
inhibitor of NO formation L-NG-monomethyl arginine (L-NMMA; 10"4 M)
markedly reduces the response. Under these conditions, inhibition of
prostaglandin formation has a weak additional inhibitory effect. (Reproduced
with permission'321).
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Figure 4 Basal formation of endothelium-derived NO in intramy-
ocardial porcine coronary arteries. In an isolated artery with
endothelium contracted with acetylcholine (Ach), bradykinin
(BK) causes full relaxation. The inhibitor of NO formation L-NG
monomethyl arginine (L-NMMA) causes endothelium-dependent
contractions (which are not mimicked by its stereoisomer D-
NMM A). Reintroduction of L-arginine (L-Arg) but not of D-argi-
nine (D-Arg) reverses the contraction. In contrast, in a
preparation without endothelium (lower panel) L-NMMA is with-
out effect. (Reproduced with permission!3;!l).
blunted ability to form NO1341. Thus, formation of
endothelium-derived NO from L-arginine occurs under
basal conditions and after stimulation with acetyl-
choline. The enzyme(s) involved (NO synthase) is Ca2+-
dependent, requires NADPH and leads to the
formation of NO and L-citrulline from L-arginine'35"37'.
Mechanism of release
Neurohumoral mediators stimulate the release of
EDRF by activating specific endothelial receptors
(see'5]). However, the signal transduction from the
receptors to the release of the relaxing factors differ. In
the porcine and canine coronary artery, endothelium-
dependent relaxation evoked by the alpha2-adrenergic
agonist UK 14,304, 5-hydroxytryptamine (Fig. 1) and
leukotriene C4 are abolished or reduced by pertussis
toxin, which irreversibly ribosylates d proteins'38"401. In
contrast, endothelium-dependent relaxation by
bradykinin, adenosine diphosphate (ADP) and particu-
larly by the ionophore A23187 remain unaffected by the
toxin'38-40'. In intramyocardial coronary arteries, neither
of the receptors is linked to a G| protein'33'. Thus, at least
two distinct biochemical pathways are involved in the
release of EDRF. Loss of functional Gi proteins in
regenerated endothelial cells causes a selective dysfunc-
tion of the serotonin-induced release of NO and porcine
coronary arteries'41'.
In freshly harvested endothelial cells of the rabbit
aorta, acetylcholine induces a transient hyperpolariza-
tion'42'. The importance of this change in membrane
potential for the release of EDRF remains uncertain,
however, as cultured endothelial cells preserve electro-
physiological responses, in particular hyperpolarization
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to acetylcholine141441. while they lose their ability to
release E D R F in response to the muscarinic agonist.
In endothelial cells in culture, bradykinin and his-
tamine, but not the Ca2~ ionophore A23187, stimulate
the metabolism of phosphoinositol, leading to the for-
mation of inositol trisphosphate which induces intracel-
lular Ca2* mobilization'45^191. Phorbol esters (which
down-regulate protein kinase C) inhibit the release of
E D R F evoked by acetylcholine or substance P. but not
that caused by the Ca :* ionophore A23187, indicating
that diacylglycerol (which is concomitantly formed after
activation of phospholipase C) is important in con-
tributing to the release of the factor stimulated by cer-
tain receptor-operated agonists1501.
Increases in intracellular Ca2+ in endothelial cells
must play a crucial role in either the production and/or
release of EDRF. Indeed, depletion of extracellular
Ca2+ inhibits endothelium-dependent relaxation of mus-
carinic agonists, but not those of the endothelium-inde-
pendent vasodilator, sodium nitroprusside'51"531. In
addition, in cultured endothelial cells, stimulation of the
release of EDRF by bradykinin, adenosine trisphos-
phate (ATP) and ADP, thrombin and mellitin is accom-
panied by an increase in cytoplasmic Ca2+
concentrations1421. The contribution of the intracellular
release of Ca2+ to the augmentation of the cytosolic level
of the ion varies; however, the sustained release of
E D R F requires the influx of extracellular Ca2+, most
likely through a receptor-operated Ca2+ channel154"591.
Indeed, in isolated blood vessels, Ca2+ antagonists such
as verapamil or dihydropyridines do not prevent
endothelium-dependent relaxation by acetyl-
cholinel60-641.
The production and/or release of E D R F requires
oxygen, since anoxia prevents relaxation induced by
acetylcholine. but not that caused by endothelium-
independent vasodilators165^1"1. In the rabbit aorta,
endothelium-dependent relaxation is reduced by agents
that inhibit mitochondrial electron transport or un-
couple oxidative phosphorylation, suggesting that the
production and/or release of the factor depends on
mitochondrial synthesis of ATP'67'.
Endothelial effects of NO
Endothelial cells contain soluble and paniculate
guanylyl cyclase and can form cGMP (Fig. 5;[681). A num-
ber of stimuli which cause the release of E D R F as well
as nitrovasodilators and exogenous NO augment the
accumulation of cGMP by cultured endothelial
cells'68"701. The accumulation is inhibited by haemoglobin
and methylene blue and augmented by superoxide dis-
mutase1691. The presence of the analogue of the cyclic
nucleotide, 8-bromo cyclic cGMP, blunts relaxation
evoked by acetylcholine and substance P, whereas ATP,
A23187 and nitrovasodilators are unaffected17'1. One
possible reason for the increase in cGMP is that E D R F
feeds back in a negative fashion on its own release by
activating the soluble guanylyl cyclase of the endothelial
cells168-69711.
Endothelium-derived NO can interact with endothe-
lin production (Fig. 5;'721). Indeed, production of the
peptide from the endothelium of intact porcine aorta
upon stimulation with thrombin is augmented in the
presence of L-NMMA and methylene blue (Fig. 6;1721)-
Since thrombin is known to cause endothelium-depen-
dent relaxation in a variety of blood vessels, this indi-
cates that the enzyme concomitantly activates the
formation of NO and endothelin in the intima of intact
blood vessels and that the former inhibits the produc-
FigureS Interaction between endothelium-derived NO and endothelin. The two
substances can interact at the level of vascular smooth muscle where NO causes
relaxation and ET, contraction, as well as at the level of the endothelium. where
NO activates soluble guanylyl cyclase (sGC) and in turn reduces thrombin-
induced endothelin production. (Reproduced with permission' '•).
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Figure 6 Modulation of the production of immunoreactive
endothelin (ir-endothelin) by the nitrovasodilator SIN-1. The
thrombin-induced production of the peptide can be prevented by
the NO donor SIN-1 and augmented by the inhibitor of soluble
guanylyl cyclase methylene blue (MB). These experiments demon-
strate that the formation of endothelin induced by thrombin can be
inhibited via the cGMP-dependent mechanism. (Reproduced with
permission1"1).
tion of the latter (Fig. 5;'73-73'). In line with that observa-
tion, superoxide dismutase (which inhibits the
breakdown of NO) as well as the non-hydrolysable ana-
logue of cGMP, 8-bromo cGMP, prevent the thrombin-
induced formation of endothelin1721. Similarly, nitrates
such as SIN-1 and nitroglycerin inhibit the production of
endothelin induced by the enzyme (Fig. 6;'74').
Release of NO by non-endothelial cells
Rat peritoneal neutrophils|7S7*l, cytotoxic activated
macrophages1771 and cerebellar cell suspensions
obtained from newborn rats are also able to synthesize
and release NO'7"1.
Vascular effects of endothelium-derived NO
In blood vessels with endothelium, the relaxation
induced by acetylcholine, histamine and the Ca:"
ionophore A23187 are associated with an increase in the
intracellular concentration of cGMP in smooth muscle
celts (Fig. 2:'7l)-""i). The rise in cGMP in the cells slightly
precedes vascular relaxation. Removal of the endothe-
lium prevents formation of the nucleotide induced by
acetylcholine. but not that evoked by sodium nitroprus-
side. nitroglycerin or exogenous NO1*'1. The inhibitor of
soluble guanylyl cylase. methylene blue, prevents for-
mation of cGMP and prevents or reverses endothelium-
dependent relaxation by acetylcholine (see'5-12-"2').
suggesting that the cyclic nucleotide mediates the vascu-
lar actionof EDRF.
In quiescent aortas of rat and rabbit, the inhibitors of
cGMP phosphodiesterase induce endothelium-depen-
dent relaxation, suggesting that in intact blood vessels
guanylyl cyclase is continuously activated1"1"". Indeed,
basal levels of cGMP are higher in preparations with.
than in those without, endothelium and are higher in
cultured vascular smooth muscle grown in co-culture
with endothelial cells than in smooth muscle grown
alone'81-83-84!.
Several mechanisms have been proposed to explain
why cGMP induces vascular relaxation, including
decreases in intracellular calcium, inhibitory effects on
phosphoinositol metabolism and on protein kinases
(Fig. 5). Rat aortas with endothelium have a lower
45Ca2* content than those without endothelium, suggest-
ing that EDRF released under basal conditions either
reduces Ca2* influx, inhibits Ca2* mobilization from
intracellular stores or augments the efflux of the ion'851.
In the rabbit aorta, endothelium-dependent relaxation
evoked by acetylcholine is associated with a reduced
Ca2~ influx'86'. Inhibitors of EDRF, such as phenidone,
prevent the response, while sodium nitroprusside and
8-bromo cGMP mimic it. Thus, EDRF induces relaxation
in part by decreasing Ca2+ entry. Furthermore, cGMP, by
activating a protein kinase, stimulates cyclic 3',5'-adeno-
sine monophosphate-dependent Ca2+ extrusion across
the sarcolemma of vascular smooth muscle'87'.
Cyclic GMP inhibits the breakdown of phosphatidyli-
nositol in vascular smooth muscle and in platelets'88"90',
but removal of the endothelium increases the hydrolysis
of phosphatidylinositide with increased accumulation of
inositol monophosphate in the aorta of the rat and rab-
bit'89'. Similar effects can be observed after lysis of the
endothelium or after inhibition of guanylyl cyclase'89!.
Finally, in the rat aorta, acetylcholine and sodium
nitroprusside decrease the incorporation of labelled
phosphor into myosin light chains'79-91-92'. Removal of the
endothelium abolishes the effect of the muscarinic ago-
nist, but not that of the nitrovasodilator. Thus, EDRF
may act through a cGMP-dependent protein kinase
which controls the phosphorylation and dephosphoryla-
tion of myosin light chains.
Antiplatelet effects of NO
Platelets also contain enzyme-soluble guanylyl
cyclase and can form cGMP (Fig. 2:'93 **'), but increased
production of cyclic nucleotide is associated with
reduced platelet adhesion and aggregation. EDRF. as
well as exogenous NO inhibit platelet adhesion to the
endothelium and platelet aggregation in vitro and in
vivo (Fig. 7:'9'"1"5'). Both also increase the content of
cGMP, and reduce the thrombin-induced rise in intra-
cellular Ca2*'*•"*'.
The potency of EDRF as an anti-aggregant and dis-
aggregant substance is comparable to that of prostacy-
clin'""1'. Prostacyclin and NO potentiate each other even
at subthreshold concentrations in their anti-aggregatory
action1"-"1"'. In the rabbit, intravenous infusions of the
muscarinic agonist carbachol increase the platelet con-
tent in cGMP and inhibit their aggregation induced by
ADPlMV. Since both effects can be prevented by the
simultaneous administration of either methylene blue
or haemoglobin. EDRF is the most likely mediator.
Interestingly, aggregating platelets release enough
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Figure 7 Endothelium and platelet-vessel wall interaction.
Platelets (top) release a variety of mediators such as adenosine
diphosphate (ADP). adenosine trisphosphate (ATP) and, 5-
hydroxy-tryptamin (serotonin: 5-HT). In addition, thromboplastin
leads to the formation of thrombin. All these platelet-derived
mediators and products of the coagulation cascade can interfere
with the endothelium to evoke the release of endothelium-derived
relaxing factor (EDRF) and prostacyclin (PGN;not shown). Both
substances, if released into the lumen of the blood vessel wall can
inhibit platelet function and reduce platelet adhesion and aggrega-
tion. EDRF and. in certain but not all blood vessels, PGI2 can also
evoke relaxation of vascular smooth muscle. Thus, by releasing
EDRF and PGK the endothelium plays a protective role in the cir-
culation by preventing platelet adhesion, aggregation and platelet-
induced vasospasm. while endothelin (GT) causes profound
contraction. (Reproduced with permission'7'.)
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Figure 8 Endothelium-dependent (• . n = 5) relaxation of aggre-
gating platelets in the normal human internal mammary artery.
Platelets activated by Krebs-Ringer Henseleit solution cause
marked relaxation in isolated arteries contracted with nore-
pinephrine. As these relaxations are prevented by endothelium
removal (• . n = 5), apyrase (O, n = 4) (to break down ATP and
ADP to AMP) and the inhibitor of NO formation L-NG-
monomethyl arginine (L-NMMA, •, n = 4), adenine nucleotides
released by the platelets must activate purinergic receptors on the
endothelium linked to the release of endothelium-derived nitric
oxide, which in turn causes vascular relaxation. (Reproduced with
permission' "*!.)
ATP and ADP to stimulate the release of endothelium-
derived NO and cause endothelium-dependent relax-
ation in normal human arteries (Fig. 8;I|O6I). Thus,
release of EDRF in response to platelet-derived prod-
ucts (Fig. 7) may provide a negative feed-back mecha-
nism inhibiting adhesion and aggregation of the
platelets at sites where they are activated.
Humoral effects of NO
EDRF released from isolated blood vessels in the dog
reduces the production of renin (demonstrated in slices
of canine kidneys)1"171. Anatomically, endothelial cells
and juxtaglomerular cells are in close proximity in the
wall of the preglomerular arterioles. Since endothelial
cells can respond to shear stress, with an increased
release of EDRF, modulation of renin release by the
factor could link changes in perfusion pressure in the
afferent arterioles with the release of renin enzyme.
Hence, endothelial cells may act as the intra-renal
baroreceptor.
In the atrium of the rat, endocardium (and endothe-
lium) removal with saponin augments the basal release
of atrial natriuretic peptide1""1. A similar effect can be
obtained with inhibitors of EDRF such as haemoglobin,
methylene blue and hydroquinone. This suggests that
EDRF released from either the endocardium or from
endothelial cells of the coronary vasculature inhibits the
release of the natriuretic peptide.
Endothelium-derived NO and nitrates
The vascular effects of exogenous nitrates are modu-
lated by the presence of endothelium11"9-1121. Indeed, in
arteries with intact endothelial cells, the relaxing effects
of sodium nitroprusside, nitroglycerin or SIN-1 (the
active metabolite of molsidomine) are reduced, com-
pared with preparations without endothelium (Fig.
9;l"l). As the inhibitor of NO formation, L-NMMA also
augments the relaxing effects of nitrates, and the activ-
ity of the endothelial L-arginine NO pathway appears to
reduce the responsiveness of blood vessels to
nitrates1""21. As the basal formation of endothelium-
derived NO is smaller in veins as compared to arteries,
this may also explain why nitrates have more pro-
nounced effects in the venous as compared to the arte-
rial circulation. One interesting clinical implication of
this phenomenon may be the fact that nitrates preferen-
tially dilate those vascular segments with dysfunctional
endothelial cells.
Nitrates can also interfere with endothelin production
stimulated by thrombin (Fig. 6f^) which may provide a
new vascular mechanism of action of nitrovasodilators
such as SIN-1 and nitroglycerin1741.
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Figure 9 Basal formation of endothelium-derived NO and the effects of therapeutic NO donor. The sydnonimine, SIN-1, causes marked
relaxation in intramyocardial porcine coronary arteries. The sensitivity to SIN-1 is more pronounced in arteries without endothelium than
in those with it. In arteries with endothelium, the inhibitor of NO formation, L-NG-monomethyl arginine (L-NMM A), markedly augments
the response, while in preparations without endothelium, the inhibitor is without effect —D—, control; —•—, L-NMMA 10~4 M; n = 4.
(Reproduced with permission1321.)
Conclusion
The endothelium is thus a source of a number of sub-
stances which can evoke a relaxation of the underlying
smooth muscle. The most important EDRF is NO which
is formed from L-arginine. Its action is mediated by
increases in cGMP in vascular smooth muscle cells, the
endothelium, platelets and certain other tissues. As a
vasodilator and inhibitor of platelet function, endothe-
lium-derived NO plays a protective role in the circula-
tion. Besides NO and prostacyclin, endothelium releases
other EDRF(s) such as endothelium-derived hyperpo-
larizing factor. The biochemical nature and physiologi-
cal importance of these substance(s) remains to be
denned.
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